Insmed, Inc. (NASDAQ:INSM) CEO Sells $13,031,123.95 in Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 129,805 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the completion of the sale, the chief executive officer now owns 233,924 shares of the company's stock, valued at $23,483,630.36. This represents a 35.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

William Lewis also recently made the following trade(s):

• On Tuesday, June 3rd, William Lewis sold 5,472 shares of Insmed stock. The stock was sold at an average price of $71.50, for a total transaction of $391,248.00.
• On Monday, June 2nd, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $71.31, for a total value of $487,047.30.
• On Tuesday, May 20th, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $67.72, for a total value of $462,527.60.
• On Tuesday, May 20th, William Lewis sold 21,057 shares of Insmed stock. The shares were sold at an average price of $67.65, for a total value of $1,424,506.05.
• On Wednesday, May 14th, William Lewis sold 3,771 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $247,415.31.
• On Tuesday, May 13th, William Lewis sold 17,442 shares of Insmed stock. The shares were sold at an average price of $66.97, for a total transaction of $1,168,090.74.
• On Thursday, May 1st, William Lewis sold 6,830 shares of Insmed stock. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10.
• On Tuesday, April 15th, William Lewis sold 6,830 shares of Insmed stock. The shares were sold at an average price of $70.16, for a total value of $479,192.80.

Insmed Trading Up 3.2%

Shares of INSM traded up $3.22 on Friday, reaching $102.68. 4,668,575 shares of the company's stock were exchanged, compared to its average volume of 2,164,388. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The stock has a market capitalization of $19.48 billion, a P/E ratio of -17.26 and a beta of 0.80. The business has a 50 day moving average price of $74.81 and a two-hundred day moving average price of $74.53. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $102.81.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. Insmed's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.06) earnings per share. Research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on INSM shares. Citigroup upgraded Insmed to a "buy" rating in a research note on Tuesday, June 10th. Bank of America increased their price objective on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insmed in a research note on Tuesday, June 10th. HC Wainwright upped their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Finally, UBS Group decreased their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and an average price target of $104.81.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of INSM. Darwin Global Management Ltd. raised its holdings in Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after purchasing an additional 2,463,261 shares during the period. Norges Bank bought a new stake in shares of Insmed in the 4th quarter valued at $126,606,000. Adage Capital Partners GP L.L.C. raised its stake in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after buying an additional 1,799,382 shares during the period. Nuveen LLC acquired a new stake in Insmed during the 1st quarter worth $88,351,000. Finally, Vanguard Group Inc. lifted its holdings in Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after acquiring an additional 1,075,796 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.